https://insights.omnia-health.com/sites/all/themes/penton_subtheme_omnia_health/images/logos/footer.png
Omnia Health Insights
Leinco partners with LJI to develop novel COVID-19 diagnostic tools
Mar 10, 2021

1 1

X

1 1

ADVERTISEMENT

Most first-generation COVID-19 vaccines are exclusively directed at the spike (S) protein on the virus surface, but the N protein is just as efficient in eliciting a strong antibody response. But most importantly, the N protein appears to be less prone to accumulating mutations than the S protein, for which a number of novel mutations have been reported over the course of the pandemic.

Next Up
Everything you need to know about COVID-19 symptoms and treatments
Start Slideshow ›